Last updated: February 14, 2026
What are the Criteria for Patentability of Biopharmaceutical Patents in the European Patent Office?
Biopharmaceutical patents must satisfy several statutory requirements under the European Patent Convention (EPC). These relate to novelty, inventive step, and industrial applicability.
Novelty
The invention must not have been disclosed publicly before the filing date. Prior disclosures include scientific publications, prior patents, or public use. For biopharmaceuticals, disclosures of similar molecules or methods can challenge novelty, including disclosure of sequences or manufacturing processes.
Inventive Step
The invention must show a non-obvious advance over existing knowledge. In biopharmaceuticals, this involves demonstrating a surprising property, specific application, or improved efficacy over prior art. Recent case law emphasizes the importance of a technically plausible rationale for inventive step.
Industrial Applicability
The invention must be capable of use in some kind of industry, including pharmaceuticals. Even a formulation with a demonstrated physical property can satisfy this criterion.
Additional Patentability Challenges
Biopharmaceutical inventions often face issues with “susceptibility to methods of treatment” exclusions under Art. 53(c) EPC, especially concerning methods of medical treatment. However, the EPO permits patenting of pharmaceutical compounds and their use in manufacturing medicaments, excluding methods of treatment per se.
How Does the EPO Assess the Enforceability of Biopharmaceutical Patents?
Enforceability depends on the patent’s strength, validity, and clarity.
Validity and Litigation
A valid patent is one that meets all EPC criteria. The EPO’s opposition or appeal proceedings can invalidate patents based on added subject matter, lack of novelty, or inventive step.
Clarity and Support
Claims must be clear and supported by the description as required by Art. 84 EPC. Patent claims in biopharmaceuticals often involve complex molecular sequences or manufacturing steps, which are scrutinized for clarity.
Duty of Disclosure
Applicants must disclose any known relevant prior art. Failure to do so can lead to patent unenforceability based on lack of novelty or sufficiency.
Pending Challenges
Biopharmaceutical patents are often challenged post-grant in litigation or opposition proceedings. Patents with broader claims face higher risks of invalidation for lack of inventive step or clarity.
What is the Scope of Claims for Biopharmaceutical Patents at the EPO?
The scope of claims is defined primarily by the language used and supported by the disclosure.
Product Claims
Biopharmaceutical patents frequently include claims on the chemical or biological product itself—e.g., a specific antibody or gene sequence. These claims are typically broad but must be fully enabled by the description.
Use Claims
Claims may specify the therapeutic application or method of use, such as treating a disease with a particular compound. These are often narrower but can be valuable for extending patent life via "Swiss-type" claims (though largely phased out under EPC rules post-2016) or medical indications.
Process Claims
Claims can extend to manufacturing methods, such as fermentation processes or purification techniques. These tend to be narrower but protect specific innovations in production.
Markush and Product-by-Process Claims
The EPO permits product claims expressed by Markush structures or "product-by-process" claims, especially relevant for complex biologics. These claim formats influence scope and enforceability.
Patent Term and Extensions
Biopharmaceutical patents typically enjoy 20 years from filing, with opportunities to apply for supplementary protection certificates (SPCs), which extend protection based on regulatory approval timelines.
How Do EPO Guidelines and Case Law Influence Patentability and Scope?
Guidelines for Examination
The EPO Guidelines (latest revision 2022) emphasize analyzing inventive step with regard to multiple prior art references, especially for biopharmaceuticals with similar sequences or functions. Clarity is scrutinized for claims involving biological sequences, often requiring sequence listing compliance.
Case Law Highlights
- T 0600/97 (Gene Sequences): Clarified that sequence disclosures must be complete and enable the invention.
- T 331/87 (Antibodies): Confirmed that claims must specify the antibody’s functional features to avoid indefinite scope.
- G 2/12 (Patent for Plant Varieties): While not directly related, influences biopharma claims involving genetic modifications.
The case law encourages precise claim language and detailed description to uphold enforceability and scope.
Summary
- Patentability: Biopharmaceutical patents must clear novelty, inventive step, and industrial applicability. Disclosure of biological sequences requires full enablement.
- Enforceability: Validity challenges typically target novelty, inventive step, clarity, or added subject matter. Clear claims supported by comprehensive description enhance enforceability.
- Scope: Claims cover compounds, therapeutic uses, and manufacturing processes. Broader product claims increase scope but face higher validity scrutiny, especially for complex biologics.
Key Takeaways
- Patentable biopharmaceutical inventions require specific, detailed disclosures, especially for biological sequences.
- Claims must be well-supported and clearly defined to withstand validity challenges.
- Broad claims offer maximum scope but face higher hurdles for validity, especially concerning inventive step.
- Opposition and litigation are common post-grant to refine scope and enforceability.
- Understanding case law and procedural guidelines improves patent strategies.
FAQs
1. Can methods of medical treatment be patented at the EPO?
No. Methods of medical treatment are excluded under Art. 53(c) EPC. Only the compounds, compositions, or manufacturing processes are patentable.
2. How does the EPO treat biological sequence disclosures?
Sequences must be fully disclosed and sufficiently enabled, meeting clarity requirements. Partial disclosures are insufficient and can jeopardize patentability.
3. Is it possible to patent a new use of an existing molecule?
Yes. Use claims for new therapeutic indications are allowed but must be supported by credible data and detailed description, particularly as Swiss-type claims are phased out.
4. What are common grounds for opposition to biopharmaceutical patents?
Lack of novelty, inventive step, insufficient disclosure, added matter, or lack of clarity are common grounds for opposition.
5. How do the EPO’s guidelines influence claim drafting?
They stress the importance of precise language, support by description, and careful consideration of prior art to avoid invalidation.
Citations
- European Patent Convention (EPC), Articles 52-57.
- EPO Guidelines for Examination, 2022.
- T 0600/97 (Gene Sequences).
- T 331/87 (Antibodies).
- G 2/12 (Patent for Plant Varieties).
